Skip to contentP
Phio Pharmaceuticals Corp.
P
PHIOPhio Pharmaceuticals Corp. Q3 2020 · 10-Q
Revenue$0.00$0.00— vs Q3 2019 Net Income-$2.31M-$2.31MN/M vs Q3 2019 EPS Diluted-$0.40-$0.40N/M vs Q3 2019 Operating Income-$2,306,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phio Pharmaceuticals Corp. · CIK 1533040 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,979,000N/M ended Sep 30, 2020 · filed Nov 10, 2020 · 41 d after period end